Patricia M. LoRusso: A Life and Career Fueled by the Fight Against Cancer

Career and Leadership Roles

Dr. LoRusso began her academic and clinical career at Wayne State University’s Barbara Ann Karmanos Cancer Institute in 1988. There, she led the institution’s Phase I Clinical Trials Program and directed the Eisenberg Center for Translational Therapeutics. Her leadership helped build one of the nation’s most productive early-phase oncology research programs.

In 2014, Dr. LoRusso was recruited to Yale School of Medicine, where she currently serves as the Amy and Joseph Perella Professor of Medicine, Chief of Experimental Therapeutics, and Associate Director for Experimental Therapeutics at Yale Cancer Center. In this role, she oversees the translation of laboratory findings into novel therapies for patients with cancer, with a particular emphasis on solid tumors.

Throughout her career, she has also been a dedicated mentor, training the next generation of oncology researchers and clinicians. Her reputation for scientific excellence and strategic vision has made her one of the most respected figures in academic oncology.

Research and Scientific Contributions

Dr. Patricia M. LoRusso is internationally regarded as one of the foremost leaders in the field of early-phase oncology drug development. Over the course of more than three decades, she has served as the principal investigator on over 100 Phase I and translational clinical trials, many of which have been first-in-human studies that introduced entirely new classes of cancer therapeutics into the clinic.

• Developed and evaluated novel targeted agents, particularly in solid tumors.
• Played a critical role in the clinical development of several drugs that have gone on to receive U.S. Food and Drug Administration (FDA) approval, including poly (ADP-ribose) polymerase (PARP) inhibitors, mitogen-activated protein kinase kinase (MEK) inhibitors, and Kirsten rat sarcoma virus (KRAS) G12C inhibitors.
• Built and led highly productive experimental therapeutics programs at both the Barbara Ann Karmanos Cancer Institute and Yale Cancer Center.
• Championed the use of molecular biomarkers, next-generation sequencing, and real-time genomic profiling to guide therapeutic decisions and patient selection in early-phase trials.
• Designed clinical trials that are scientifically rigorous yet mindful of the patient experience, taking into consideration toxicity profiles, quality of life, and logistical feasibility.
• Early advocate for decentralizing access to trials and expanding eligibility criteria to include more diverse patient populations, thus increasing inclusivity in cancer research.

Honors and Awards

• Elected a Fellow of the American Association for Cancer Research (AACR) Academy in 2023.
• Served as President of the AACR for the 2024–2025 term.
• Awarded the prestigious AACR–Joseph H. Burchenal Award for Outstanding Achievement in Clinical Cancer Research in 2022.
• Nominated as a Fellow of the American Society of Clinical Oncology (ASCO).
• Received the Michigan State University Distinguished Alumni Award.
• Nominated as one of the MGH Cancer Center’s “100” honorees for her impact in cancer care.